Pressure
BioSciences Announces Launch of FDA-Registered Hand Sanitizer as
First Product Developed Through Pending Merger
Partners
South
Easton, MA -- May 14, 2020 -- InvestorsHub NewsWire
-- Pressure
BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader
in the development and sale of broadly enabling, pressure-based
instruments, consumables, and platform technology solutions
to the
worldwide
biotechnology,
biotherapeutics, cosmeceuticals,
nutraceuticals, and
food
&
beverage
industries,
today announced
that
following its previously announced pending
merger
(Click
Here) and name change
to Availa Bio, that the newly branded,
publicly-traded company will be
entering the hand sanitizer market through
the
founders of Cannaworx.
The
custom-designed,
next generation, premium hand
sanitizer will be
the
first product released under the new holding
company Availa
Bio.
The
owners of privately held Cannaworx, Inc. have obtained FDA
registration for the newly developed hand sanitizer, as well as an
NDC (National Drug Code) number. The product is being manufactured
in a fully compliant, GMP-certified facility. Initial packaging
will be in 250/500 ml. bottles, with 125 ml., 1 liter, and 1gallon
sizes available by Fall 2020. The product contains 75%
alcohol in a proprietary blend of other
reagents.
Hand
sanitizers are liquid, gel, or foam anti-microbial products
that have
been
shown to be effective in
killing
human
disease-causing pathogens (e.g.,
viruses, bacteria, fungi) on the hands. Most hand sanitizers use
alcohol as their active and most prominent ingredient.
Hand
sanitizers are believed to be
faster, more efficient, and easier on the skin than repeated
handwashing. They are often used when hand washing with soap
and water is not convenient or possible.
According to a 2019
report by Radiant Insights, the global hand sanitizer market is
expected to reach $5.5 billion by 2024 (Click
Here).
Availa
Bio will be led by Jim Morrison (Click
Here), the former
President of L'Oreal, Sexy Hair,
StarShop, and
Graham Webb. In addition to his
remarkable career at the helm of several prominent beauty and
cosmeceutical companies, Mr. Morrison
also
has
had
a long
and distinguished history of collaborating with celebrities to
design and launch beauty and personal care lines, including Kylie
Jenner, Britney
Spears, Christie Brinkley, and Rob Lowe. Mr.
Morrison is
universally regarded as one of the top brand strategists in the
personal care space worldwide.
Mr.
Morrison explained the new developments: "Over the past few months,
growing shortages of hand sanitizers have been reported in stores
across the USA. In addition, the opportunity to bring leading
scientists in skin care and in formulations technology together
into an
FDA-registered premium grade
dermatological hand sanitizer has been largely unanswered. In
discussing these issues with the scientific and business teams of
the three companies that are merging into Availa Bio, we
saw
the opportunity
to fill a strong
demand in the market with our proprietary
dermatological
formulation, to
develop a high-quality registered
hand
sanitizer."
The
Letter of Intent between Cannaworx and SkinScience Labs, and the
Letter of Intent between PBI and Cannaworx, Inc. are subject to
certain closing conditions, including completion of all due
diligence and acquisition financing.
About
Pressure
BioSciences,
Inc.
Pressure
BioSciences,
Inc.
(OTCQB:
PBIO)
is
a
leader
in
the
development
and
sale
of
innovative,
broadly
enabling,
pressure-based
solutions
for
the
worldwide
life
sciences
and
other
industries.
Our
products
are
based
on
the
unique
properties
of
both
constant
(i.e.,
static)
and
alternating
(i.e.,
pressure
cycling
technology,
or
PCT)
hydrostatic
pressure.
PCT
is a
patented
enabling
technology
platform
that
uses
alternating
cycles
of hydrostatic
pressure
between
ambient
and
ultra-high
levels
to
safely
and
reproducibly
control
bio-molecular
interactions
(e.g.,
cell
lysis,
biomolecule
extraction).
Our
primary
focus
is
in
the
development
of
PCT-based
products
for
biomarker
and
target
discovery,
drug
design
and
development,
biotherapeutics
characterization
and
quality
control,
soil
&
plant
biology,
forensics,
and
counter-bioterror
applications.
Additionally,
major
new
market
opportunities
have
emerged
in
the
use
of
our
pressure-based
technologies
in
the
following
areas:
(1)
the
use
of
our
recently
acquired,
patented
technology
from
BaroFold,
Inc.
(the
"BaroFold"
technology)
to
allow
entry
into
the
bio-pharma
contract
services
sector,
and
(2)
the
use
of
our
recently-patented,
scalable,
high-efficiency,
pressure-based
Ultra
Shear
Technology
("UST")
platform
to
(i)
create
stable
nanoemulsions
of
otherwise
immiscible
fluids
(e.g.,
oils
and
water)
and
to
(ii)
prepare
higher
quality,
homogenized,
extended
shelf-life
or
room
temperature
stable
low-acid
liquid
foods
that
cannot
be
effectively
preserved
using
existing
non-thermal
technologies.
Forward
Looking
Statements
This
press
release
contains
forward-looking
statements.
These
statements
relate
to
future
events
or
our
future
financial
performance
and
involve
known
and
unknown
risks,
uncertainties
and
other
factors
that
may
cause
our
or
our
industry's
actual
results,
levels
of
activity,
performance
or
achievements
to
be
materially
different
from
any
future
results,
levels
of activity,
performance
or
achievements
expressed,
implied
or
inferred
by
these
forward-looking
statements.
In
some
cases,
you can
identify
forward-looking
statements
by
terminology
such
as
"may,"
"will,"
"should,"
"could,"
"would,"
"expects,"
"plans,"
"intends,"
"anticipates,"
"believes,"
estimates,"
"predicts,"
"projects,"
"potential"
or
"continue"
or
the
negative
of
such
terms
and
other
comparable
terminology.
These
statements
are
only
predictions
based
on
our
current
expectations
and projections
about
future
events.
You
should
not
place
undue
reliance
on
these
statements.
In
evaluating
these
statements,
you
should
specifically
consider
various
factors.
Actual
events
or
results
may
differ
materially.
These
and
other
factors
may cause
our actual
results
to
differ
materially
from
any
forward-looking
statement.
These
risks,
uncertainties,
and
other
factors
include,
but
are
not
limited
to,
the
risks
and
uncertainties
discussed
under
the
heading
"Risk
Factors"
in
the
Company's
Annual
Report
on
Form
10-K
for
the
year
ended
December
31,
2019,
and
other
reports
filed
by
the
Company
from
time
to
time
with
the
SEC.
The
Company
undertakes
no
obligation
to
update
any
of
the
information
included
in this
release,
except
as
otherwise
required
by law.
For
more
information
about
PBI
and
this
press
release,
please
click
on the
following
website
link:
http://www.pressurebiosciences.com
Please
visit
us
on
Facebook,
LinkedIn,
and
Twitter.
Press
Contacts:
Richard
T.
Schumacher,
President
&
CEO
(508)
230-1828
(T)
Jeffrey N. Peterson,
Chairman
(650)
703-8557
(T)
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pressure Biosciences (CE) (USOTC:PBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024